226 related articles for article (PubMed ID: 33234363)
1. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
[TBL] [Abstract][Full Text] [Related]
2. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
4. Natural compound glycyrrhetinic acid protects against doxorubicin-induced cardiotoxicity by activating the Nrf2/HO-1 signaling pathway.
Cheng Y; Wu X; Nie X; Wu Y; Zhang C; Lee SM; Lv K; Leung GP; Fu C; Zhang J; Li J
Phytomedicine; 2022 Nov; 106():154407. PubMed ID: 36070662
[TBL] [Abstract][Full Text] [Related]
5. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
[TBL] [Abstract][Full Text] [Related]
8. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
[TBL] [Abstract][Full Text] [Related]
10. Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating antiangiogenic and proapoptotic pathways in vitro and in vivo.
Li J; Tang F; Li R; Chen Z; Lee SM; Fu C; Zhang J; Leung GP
J Nutr Biochem; 2020 Mar; 77():108268. PubMed ID: 31830590
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional hybrid nanoconstructs facilitate intracellular localization of doxorubicin and genistein to enhance apoptotic and anti-angiogenic efficacy in breast adenocarcinoma.
Shukla RP; Dewangan J; Urandur S; Banala VT; Diwedi M; Sharma S; Agrawal S; Rath SK; Trivedi R; Mishra PR
Biomater Sci; 2020 Mar; 8(5):1298-1315. PubMed ID: 31903460
[TBL] [Abstract][Full Text] [Related]
12. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells.
Dallons M; Alpan E; Schepkens C; Tagliatti V; Colet JM
Cells; 2020 Sep; 9(10):. PubMed ID: 32992522
[TBL] [Abstract][Full Text] [Related]
13. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.
Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T
Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Nidhyanandan S; Boreddy TS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Narayanan S
Eur J Pharmacol; 2015 Oct; 764():508-519. PubMed ID: 26209365
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
[TBL] [Abstract][Full Text] [Related]
16. Dietary isoflavone daidzein synergizes centchroman action via induction of apoptosis and inhibition of PI3K/Akt pathway in MCF-7/MDA MB-231 human breast cancer cells.
Kaushik S; Shyam H; Sharma R; Balapure AK
Phytomedicine; 2018 Feb; 40():116-124. PubMed ID: 29496164
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells.
Wu GS; Lu JJ; Guo JJ; Huang MQ; Gan L; Chen XP; Wang YT
Pharmacol Rep; 2013; 65(2):453-9. PubMed ID: 23744430
[TBL] [Abstract][Full Text] [Related]
18. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
19. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
20. Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells.
Choupani J; Alivand MR; M Derakhshan S; Zaeifizadeh M; S Khaniani M
J Cell Physiol; 2019 Jun; 234(6):9093-9104. PubMed ID: 30317622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
